BREAST CANCER PROGRAM AREA REPORT
September 1977 to October 1978

Program Coordinators: Dr. Nathaniel I. Berlin
Dr. Haruo Sugano


Administrative Report and Scientific Summary

MEETINGS, SEMINARS, AND CONFERENCES
The Annual Meeting of the Breast Cancer Program Area and a symposium entitled "Hormones, Receptors, and Breast Cancer" were held in Honolulu, Hawaii, on March 6 and 7, 1978. The proceedings of this symposium were published as the monograph Progress in Cancer Research and Therapy: Hormones, Receptors, and Breast Cancer, 1978 (see Conference Reports following this Program Area Report). The symposium was organized by Dr. W.L. McGulre, University of Texas, and Dr. K. Matsumoto Osaka University, and addressed two major subjects: Session I: Hormones and Receptors in Human Breast Cancer in Japan and the United States; and Session II: Basic Studies on Endocrine Therapy in Breast Cancer.
Scientific results obtained were as follows:
Hormones and Receptors in Human Breast Cancer in Japan and the U.S.A. -Investigations of 1,000 Japanese and 1,000 American Patients
In Japan, the incidence of breast cancer is remarkably lower than in the United States. Japanese breast cancer patients have a better survival rate than American breast cancer patients. However, the survival advantage of Japanese patients cannot be explained by tumor estrogen (ER) and progesterone (PgR) receptor incidence, since the incidence was slightly lower in Japanese patients than in American patients. The slightly lower incidence in Japan is due mainly to the significantly lower incidence of ER In postmenopausal Japanese (55 percent) than in postmenopausal American patients (75 percent). In both countries, the response rates to endocrine therapies were 50 to 70 percent for ER + and/or PgR + tumors, and less than 10 percent for negative tumors. Assays of ER and/or PgR were shown to be useful markers for predicting the response to endocrine therapy.
Basic Studies on Endocrine Therapy in Breast Cancer
Antiestrogens such as tamoxifen and epitiostanol (Shionogi Company) were shown to be useful materials for endocrine therapy in breast cancers. Basic mechanisms of antihormorie action of these antiestrogens were shown and discussed. The growth of mammary tumors induced in rats (DMBA-tumors) and mice (pregnancy-dependent tumors) was shown to be dependent upon the action of multiple hormones such as prolactin and estrogen. However, growth of Shionogi carcinoma in mice was stimulated only by androgens. These animal tumors are thought to be adequate model tumors for investigating endocrine therapy in human breast cancer.
The following problems remain to be investigated in the future:
Difference of ER Incidence Between Post-menopausal Japanese and American Breast Cancer Patients
The incidence of breast cancer is much higher in the postmenopausal American than in the premenopausal American and in both premenopausal and postmenopausal Japanese patients. Investigations seeking an explanation of the difference in ER incidence would seem to be valuable, in order to determine the pathogenesis of some human breast cancers.
Tumor Hormone Receptors and Response to Endocrine Therapy
ER- was shown to be a good marker for selecting endocrine-resistant tumor. However, about 30 to 50 percent of ER + and/or PgR + tumors were endocrine-resistant tumors. Investigations on various receptor systems are required in order to obtain ideal markers for selecting endocrine-responsive tumors. The basic investigations using animal tumor models suggest that endocrine therapy may be more effective for controlling the growth of human breast cancers in the early stage of development. Extensive investigations on endocrine therapy for early breast cancer should be attempted in the near future.
Mechanism of Hormone Dependent Growth
The mechanism should be clarified in order to establish ideal endocrine therapy for human breast cancers.
Hormone Receptors and Histopathology
The relationship between ER, PgR, androgen, and prolactin receptors and histopathology should be examined in breast, endometrial, and prostate cancers. The participants at this annual meeting and symposium found the presentations and discussions to be extremely stimulating and productive. Since there are great differences in the incidence and prognosis of breast cancer between Japanese and American patients, studies on breast cancers are very appropriate to the U. S. - Japan Cooperative Cancer Research Program. In this seminar, it was possible to clarify many important points on the endocrine control and endocrine therapy of breast cancer. In light of the important and rewarding exchange of information resulting from this seminar, it is hoped that cooperation between Japan and the United States in breast cancer research will continue into the future.
The presentations at this seminar have been published in a monograph, Progress in Cancer Research and Therapy; Hormones, Receptors, and Breast Cancer, Volume 10, pp. 1-369 (New York: Raven Press, 1978). Acknowledgements are given to the National Cancer Institute (NCI) and the Japan Society for the Promotion of Science. For a listing of the presentations, see Conference Reports following this Program Area Report.

EX CHANGE OF SCIENTISTS
1. Dr. Hiroki Koyama from the Osaka Adult Disease Center served as a visiting scientist with Dr. Carbone at Madison, Dr. Ahman at Rochester, Dr. Berlin at Chicago, Dr. Dao at Buffalo, Dr. Muggia at Bethesda, and Dr. Carter at San Francisco. Dr. Koyama also at-tended the annual meeting of the National Surgical Adjuvant Breast Project (NSABP) held In Miami. The purpose of his visit was to investigate the present status of chemotherapy for breast cancer in the United States and to discuss mutual problems of adjuvant and combined modality therapy for breast cancer. The itinerary for this visit follows this Program Area Report.
2. Dr. Robert Yonemoto from the City of Hope Medical Center, Duarte, California, planned to visit Hokkaido University and Cancer Institute, Tokyo, but due to unexpected personal reasons, the visit has been postponed until 1979.

EX CHANGE OF MATERIALS
A program for review of histopathological material on breast cancer in Japan has been developed by Dr. William Hartmann of Vanderbilt University, Nashville, Tennessee. As a result of this program, Dr. Goi Sakamoto visited the United States to collaborate on further histopathological slides to compare the difference in specimens between the American and Japanese patients.

Future Activities, 1978-1979

MEETINGS, SEMINARS, AND CONFERENCES
A seminar on "Breast Cancer Treatment" is being organized by Drs. N.I. Berlin, H. Sugano, S. Carter, and Y. Sakurai. The projected date and place will be February 26 and 27, 1979, at the Palace Hotel, Tokyo.
The purpose of this seminar is to clarify and compare the therapeutic effects of combined modality treatment on breast cancer in both countries. The subjects will be as follows:
• Comparison of Breast Cancer Among Japanese and American Females
• Screening for Breast Cancer
• Surgical Treatment
• Specific Chemotherapy for Breast Cancer
• Chemotherapy for Metastatic Breast Cancer and Adjuvant Chemotherapy
• Hormone Receptors and Therapy
• Animal Models for Breast Cancer
• Future Prospect of Chemotherapy for Breast Cancer.
An agenda and list of participants for this symposium may be found in Conference Reports following this Program Area Report.
A preliminary meeting is tentatively being planned on "Breast Cancer in the Atomic Bomb Survivors." This meeting is being organized by Dr. Donald E. Henson and Dr. Shoji Tokuoka for May or June, 1979, at the Department of Pathology, Vanderbilt University.
Dr. Donald E. Henson, National Cancer Institute (NCI), and Dr. Stuart C. Finch, Vice Chair-man and Chief of Research, Radiation Effect Research Foundation (RERF, formerly ABCC) Hiroshima, have talked about the possibility of a joint study on breast cancer in victims of the atomic bomb in Hiroshima and Nagasaki under the cooperation of the NCI and RERF with close liaison to the U.S.-Japan Cooperative Cancer Research Program. The purpose of this study is to review the incidence and distribution of different histological types of breast cancer in persons exposed to radiation from the atomic bomb. The preliminary meeting is to take place in the United States, perhaps in Nashville in May or June 1979, and the pathological review will take place in Japan, perhaps in Hiroshima in late 1979 or early 1980. Funds for travel expenses for the participants will be provided by the U.S.-Japan Cooperative Cancer Research Program.

EXCHANGE OF SCIENTISTS
1. Dr. Robert Yonemoto from the City of Hope Medical Center, Duarte, California, is planning to visit Dr. Hiroshi Kobayashi, Hokkaido University, and Dr. Haruo Sugano, Cancer Institute, Tokyo, in June 1979.
2. Dr. Masayoshi Tokunaga, from Kagoshima University, has tentative plans to visit the National Cancer Institute, Bethesda, and Dr. W. Hartmann at Vanderbilt University.

EX CHANGE OF MATERIALS
Tentative plans are being made to exchange histological materials for newer classification schemes on breast cancer.

FIVE-YEAR SUMMARY REPORT
During the first five years of the Breast Cancer Research Program Area, information has been successfully exchanged between Japan and the U.S. through the meetings held in Japan, Hawaii, and the United States. A number of Japanese scientists have been invited to the Breast Cancer Task Force meetings held in the United States and this has served to provide them with a broadly based summary of work supported by the National Cancer Institute (NCI). There have been a number of visiting scientists, both from Japan to the United States and from the United States to Japan. There have been no specific research protocols initiated, although collaborative efforts have been started. Dr. Gilbert Friedell's collaborative efforts during this period did not arise from the cooperative group, but are an example of cooperative efforts that began in the last five years.
The past five years were a period of great cooperative activity. A system for the exchange of information on a regular basis has been developed. It has been possible to learn what types of cancer research are being accomplished in Japan, and precisely where breast cancer research is being carried out in Japan. All the participants have learned much about the characteristics of breast cancer in Japan. In turn, the Japanese investigators have gained real insight into breast cancer research in the United States.
A number of Japanese investigators have taken up leads, particularly in the hormonal receptor field, that came from work started in the United States. Excellent cooperative efforts were developed in basic and clinical research on breast cancer.

Other Collaborative Activities

BREAST CANCER TASK FORCE
The United States Breast Cancer Task Force (BCTF) has been involved in meetings on collaborative efforts in breast cancer with the U.S.-Japan Cooperative Cancer Research Pro-gram. Ongoing activities in breast biology and breast cancer, in particular, are usually reported to the Japan Mammary Cancer Society.
The Japanese coordinator for the society and the BCTF is:
Dr. Masao Fujimori
Saitama Cancer Center
Urawa, Japan

Several Japanese investigators have constituted working groups and have selected a coordinator for their group activities. In the mammary tumor virus area, cooperation with the BCTF is maintained through:
Dr. Haratura Tanaka
Institute for Virus Research
Kyoto University
Sakyo-ku, Kyoto, Japan

Dr. Yoji Ikawa
Laboratory of Viral Oncology
Cancer Institute
Japan Foundation for Cancer Research
37-1 Kamilkebukuro 1-chome
Toshima-ku, Tokyo 170, Japan

The following investigators, constituting the biology and endocrinology groups, were sent to the BCTF to facilitate direct contact among independent researchers:

Japanese Study Group on Hormone Receptors of Breast Cancer
Keishi Matsumoto. M.D. (Chairman) Professor.
Institute for Cancer Research. Osaka University Medical School. kita-ku. Osaka 530
(06-443-5531)

Osahiko Abe, M.D. Professor, Department of Surgery, Keio University Medical School.
Shinjuku-ku, Tokyo 160
(03-353- 1211)

Ryohei Okamoto, M. D. Professor. Tokyo Medical and Dental University, Bunkyo-ku. Tokyo 113
(03-813-6111)

Osamu Takatani, M.D. Head. Department of Medicine, National Cancer Center Hospital.
Chuo-ku, Tokyo 104
(03-542-2511)

Ryoji Nagai, M.D. Professor. Depelrtment of Surgery, Nagoya City University Medical School, Mizuho-ku, Nagoya 467
(052-851-5511)

Yasuo Nomura, M.D. Head, Department of Breast Surgery, National Kyushu Cancer Center Hospital, Minami-ku. Fukuoka 815
(092-541-3231)

Masaru Izuo, M.D. Professor, Department of Surgery, Gunma University Medical School.
Maebashi 371
(0272-31-7221)

Junzo Kato, M.D. Associate Professor, Department of Obstetrics and Gynecology, Teikyo University Medical School, Itabashi-ku. Tokyo 173
(03-964-1211)

Hiroo Takikawa, Ph.D. Professor. Institute for Endocrine Research, Gunma University, Maebashi 371
(0272-31-7221)

Bun-ichi Tamaoki, Ph.D. Chief. National Institute of Radiological Sciences. Anagawa-4-chome, Chiba 280
(0472-51 -2111)

Haruo Sugano, M.D. Director. Cancer Institute. Japanese Foundation for Cancer Research. Toshima-ku, Tokyo 170
(03918-0111)

Japanese Study Group on Mammary Cancer Biology
Ryo Fukunishi, M.D. Department of Pathology, Ehime University School of Medicine, Matsuyama 790
(089-964-3811)

Munemitsu Hoshino, M.D. Laboratory of Ultra-structure Research, Aichi Cancer Center Research Institute, Chikusa-ku, Nagoya 464
(052-762-6111)

Yoji Ikawa, M.D. Department of Viral Oncology. Cancer Institute, Tokyo 170
(03-918-0111)

Kiyoshi Koto, M.D. Department of Pathology, School of Medicine Osaka University, Suita, Osaka
565 (06-443-5531)

Akio Matsuzawa, Ph.D. Laboratory Animal Research Center, Institute of Medical Science, University of Tokyo, P.O. Takanawa, Tokyo 108
(03-443-8111)

Sotokichi Morif, M.D. Department of Pathology, Kansai Medical University. Moriguchi, Osaka 570 (06-992-1001)

Hiroshi Nagasawa, Ph.D. Pharmacology Division, National Cancer Center Research Institute, Chuo-ku, Tokyo 104
(03-542-2511)

Yasuaki Nishizuka, M.D. Laboratory of Experimental Pathology, Aichi Cancer Center Research Institute, Chikusa-ku. Nagoya 464
(052-762-6111)

Teruyo Sakakura, M.D. Laboratory of Experimental Pathology, Aichi Cancer Center Research Institute, Chikusa-ku, Nagoya 464
(052-762-6111)

Goi Sakamoto, M.D. Department of Pathology. Cancer Institute. Tokyo 170
(03-918-0111)

Harutura Tanaka, M.D, Institute for Virus Research, Kyoto University, Sakyo-ku, Kyoto 606
(075-751-4012)

Yoshihiko Tsubura, M.D. Department of Pathology, Nara Medical College, Kashiwara, Nara 634
(074-422-3051)

Reiko Yanai, Ph.D. Pharmacology Division, National Cancer Center Research Institute, Chuo-ku, Tokyo 104
(03-542-2511)

Kenjiro Yokoro, M.D. Department of Pathology, Research Institute for Nuclear Medicine and Biology, Hiroshima University, Hiroshima 734
(0822-51-1111)

Hiroki Yoshida, M.D. Department of Pathology, Ehime University School of Medicine, Matsuyama 790
(089-964-3811)




SYMPOSIUM: HORMONES, RECEPTORS, AND BREAST CANCER
Honolulu, Hawaii
March 6-7, 1978

AGENDA
March 6, 1978
Session I. Hormones and Receptors in Human Breast Cancer in Japan and U.S.A.
8:45 a.m. An Opening Address Dr. N. I. Berlin
9:00 a.m. ER and Endocrine Responsiveness Dr. Y. Nomura
9:20 a.m. ER and Endocrine Responsiveness Dr. E. DeSombre
9:40 a.m. ER and Endocrine Responsiveness Dr. J. Wittliff
10:00 a.m. ER and Endocrine Responsiveness Dr. M. Lippman
10:20 a.m. Discussion
11:00 a.m. PgR and Endocrine Responsiveness Dr. W. L. McGuire
11:20 a.m. PgR and Endocrine Responsiveness Dr. K. Matsumoto
11:40 a.m. Discussion
12:00 noon LUNCH
1:30 p.m. Receptors and Histopathology Dr. H. Sugano
1:50 p.m. Receptors and Histopathology Dr. P. Rosen
2:10 p.m. Discussion
2:30 p.m. Hormone Action in Tissue Culture Dr. W. L. McGuire
2:50 p.m. Hormone Action in Tissue Culture Dr. M. Lippman
3:10 p.m. Hormone Action in Tissue Culture Dr. B. Leung
3:30 p.m. Discussion

March 7, 1978
Session II. Basic Studies on Endocrine Therapy in Breast Cancer
9:00 a.m. Mechanisms of Antihormone Action Dr. J. Clark
9:20 a.m. Mechanisms of Antihormone Action Dr. B. Katzenellenbogen
9:40 a.m. Discussion
10:10 a.m. Antihormones in Breast Cancer Dr. J. Kato
10:30 a.m. Antihormones in Breast Cancer Dr. E. DeSombre
10:50 a.m. Discussion
11:20 a.m. LUNCH
1:00 p.m. Steroid Metabolism in DMBA Tumors Dr. B. Tamaoki
1:20 p.m. Growth of DMBA Tumors by Hormones Dr. B. Leung
1:40 p.m. Discussion
2:10 p.m. Hormone Dependent Mouse Tumors Dr. A. Matsuzawa
2:30 p.m. Shionogi Carcinoma 115 Dr. K. Matsumoto
2:50 p.m. Pohyamines in Mammary Tissues Dr. T. Oka
3:10 p.m. Discussion
3:40 p.m. Closing Address Dr. H. Sugano

PARTICIPANTS

JAPAN

Dr. H. Sugano*
(Pathology)
Director, Cancer Institute

Dr. K. Matsumoto
(Pathology)
Professor, Osaka University
Medical School of Pathology

Dr. Y. Nomura
(Surgery)
Head, National Kyushu Cancer Center

Dr. J. Kato
(Endocrinology)
Associate Professor
Teikyo University Medical School, Gynecology

Dr. B. Tamaoki
(Steroids)
Chief, National Institute for
Radiation Science Pharmacology

Dr. A. Matsuzawa
(Biology)
Instructor, Institute of Medical Science
Tokyo University

UNITED STATES

Dr. W. L. McGuire*
(Endocrinology)
Professor, University of Texas, Medicine

Dr. J. Clark
(Molecular Biology)
Associate Professor
Baylor College of Medicine, Cell Biology

Dr. E. DeSombre
(Molecular Biology)
Associate Professor
University of Chicago
Ben May Laboratory

Dr. P. M. Gullino**
(Cell Biology)
Director
Breast Cancer Task Force (BCTF)
National Cancer Institute

Dr. N. I. Berlin
(Physiology)
Director
Northwest University Medical School
Cancer Center

Dr. B. Kazenellenbogen
(Biochemistry)
Associate Professor
University of Illinois, Physiology

Dr. B. Leung
(Biochemistry)
Senior Scientist
Cedars-Sinai Medical Center, Biochemistry

Dr. M. Lippman
(Biochemistry)
Senior Investigator
National Institutes of Health, Medicine

Dr. P. P. Rosen
(Pathology)
Associate Professor
Memorial Hospital, Pathology

Dr. J. Wittliff
(Biochemistry)
Chairman, University of Kentucky
Medical School, Biochemistry

Dr. T. Oka
(Biochemistry)
Senior Investigator
National Institutes of Health
Biochemistry and Metabolism

*Organizer
**Observer


PRESENTATIONS AT THE SYMPOSIUM ON HORMONES, RECEPTORS, AND BREAST CANCER

The following reports were published in Progress in Cancer Research and Therapy' Hormones, Receptors, and Breast Cancer, Volume 10, edited by William L. McGuire, M.D. (New York: Raven Press, 1978, pp. 1-369).

Estrophilin and Endocrine Responsiveness of Breast Cancer
Eugene R. DeSombre, Geoffrey L. Greene, and Elwood V. Jenson

Clinical Usefulness of Estrogen Receptor Assay in Early and Advanced Breast Cancer
Y. Nomura, J. Yamagata, H. Kondo, K. Kanda, and K. Takenaka

Progesterone Receptors in Breast Cancer
William L. McGuire and Kathryn B. Horuwitz

Progesterone and Estrogen Receptors in Japanese Breast Cancer
K. Matsumoto, H. Ochi, Y. Nomura, O. Takatani, M. Izuo, R. Okamoto, and H. Sugano

Hormone Receptors and Histopathology in Japanese Breast Cancer
H. Sugano, G. Sakamoto, A. Sakamoto, Y. Nomura, O. Takatani, and K. Matsumoto

Estrogen Receptor Protein (ERP) and the Histopathology of Human Mammary Carcinoma
Paul Peter Rosen, Celia J. Menendez-Botet, Ruby T. Senie, Morton K. Schuwartz, David Schottenfeld, and Cist H. Farr

Studies of Steroid Hormone Effects on Human Breast Cancer Cells in Long-Term Tissue Culture
Jeannine S. Strobl and Marc E. Lippman

Mechanism of Action of Estrogen Antagonist: Relationship to Estrogen Receptor Binding and Hyperstrogenization
J. H. Clark, J. W. Hardin, S. A. McCormack, and H. A. Padykula

Basic Mechanism of Antiestrogen Action Benita S. Katzenellenbogen

Epitiostanol, a Steroidal Anti-Estrogen Having Anti-Mammary Tumor Activity
Takashi Hori, Tamotsu Miyake, Kenichi Takeda, and Junzo Kato

Studies on the Antiestrogen C1628 in Relation to Breast Cancer
Eugene R. DeSombre and C. Richard Lyttle

Steroid Metabolism in Experimental Mammary Tumor Induced by 7,12-Dimethyl Benz(a) anthracene
Bun-ichi Tamaoki, Makoto Mori, Masatsugu Kita-mura, and Takeshi Tominaga

Hormonal Dependency of Experimental Breast Cancer
Benjamin S. Leung

Cyioplasmic Progesterone Receptor in Mouse Mammary Tumors
Akio Matsuzawa, Tadashi Yamamoto, and yukio Mizuno

In Vitro and In Vivo Studies in Androgen-Dependent Shlonogi Carcinoma 115
K. Yamaguchi, B. Sato, S. Okamoto, Y. Kitamura, and K. Matsumoto

Pohyamines in Growth and Development of Mam-mary Gland
Takami Oka, Tadashi Sakai, David W. Lundgren, and John W. Perry

Steroid Binding Proteins of Mammary Tissues and Their Clinical Significance in Breast Cancer
James L. Wittliff, Walter M. Lewko, Daniel C. Park, Timothy E. Kute, DeWitt T. Baker, Jr., and Leslie N. Kane



U.S. -JAPAN SEMINAR ON BREAST CANCER TREATMENT
Palace Hotel, Tokyo
February 26-27, 1979

AGENDA
Monday, February 26
9:30 a.m. Session I Chairman-Dr. N. I. Berlin
Comparison of Breast Cancer Among Japanese and American Females Dr. Goi Sakamoto
10:00 a.m. COFFEE
10:30 a.m. Session II Chairman-Dr. H. Sugano
Screening for Breast Cancer Dr. Nathaniel I. Berlin
Dr. Kenji Inoue
11:30 a.m. Session III Chairman-Dr. T. Kajitani
Surgical Treatment Dr. William Donegan
Dr. Keijiro Kuno
12:30 p.m. LUNCH
2:00 p.m. Session IV Chairman-Dr. Y. Sakurai
Specialities of Chemotherapy for Breast Cancer Clinical Aspect Dr. Makoto Ogawa
Development of Drugs for Breast Cancer
Dr. Stephen Carter
3:00 p.m. COFFEE
3:30 p.m. Session V Chairman-Dr. S. Carter
Chemotherapy for Metastatic Breast Cancer and Adjuvant Chemotherapy Dr. Minoru Yoshida
Dr. Kanji Kubo
Dr. Osahiko Abe
Chairman-Dr. H. Koyama
Dr. William Donegan
Dr. Masaru Izuo
5:30 p.m. Adjourn
6:30-8:30 p.m. Reception at Tsuru Room

Tuesday, February 27
9:00 a.m. Session V Chairman-Dr. W. Donegan
Chemotherapy for Metastatic Breast Cancer and Adjuvant Chemotherapy (continued) Dr. Hiroki Koyama
Dr. Douglas Tormey
10:00 a.m. COFFEE
10:30 a.m. Session VI Chairman-Dr. D. Tormey
Hormone Receptors and Therapy Dr.Yasuo Nomura
Dr. William McGuire
Dr. Keishi Matsumoto
12:00 noon LUNCH
1:30 p.m. Session VII Chairman-Dr. W. McCuire
Animal Models for Breast Cancer Dr. Takashi Tsuruo
Dr. Osahiko Abe
Dr. Daniel Griswold
3:00 p.m. COFFEE
3:30 p.m. Chairman-Dr. K. Matsumoto
Dr. Hiroshi Nagasawa
Dr. Y. S. Cho-Chung
4:30 p.m. Session VIII Chairman-Dr. N. I. Berlin
Future Prospect of Chemotherapy for Breast Cancer Dr. Yoshio Sakurai
Dr. Stephen Carter
Dr. William McGuire
5:00 p.m. Closing Remarks and Adjournment Dr. Robert R. Omata
Dr. Nathaniel I. Berlin
Dr. Haruo Sugano


PARTICIPANTS

UNITED STATES

Dr. Nathaniel I. Berlin
Director, Cancer Center Northwestern University Medical School
303 East Chicago, Ward 3-332
Chicago, Illinois 60611, U.S.A.

Dr. Stephen Carter
Director Northern California Cancer Program
P.O. Box 10144
Palo Alto, California 94394, U.S.A.

Dr. Y. S. Cho-Chung
Natlonal Cancer Institute
Laboratory of Pathophysiology
Building 10, Room 5B36
Bethesda, Maryland 20014, U.S.A.

Dr. William L. Donegan
Milwaukee County General Hospital
Department of Surgery
8700 W. Wisconsin Avenue
Mllwaukee, Wisconsin 53226, U.S.A.

Dr. Daniel Griswold, Jr.
Southern Research Institute
200 Ninth Avenue S
Birmingham, Alabama 35205, U.S.A.

Dr. William L. McGuire
Professor of Medicine
University of Texas
Health Science Center at San Antonio
7703 Floyd Curl Drive
San Antonio, Texas 78284, U.S.A.

Dr. Douglas Tormey
Associate Professor
University of Wisconsin
Cancer Center
Madison, Wlsconsin 53706, U.S.A.

Dr. Robert R. Omata
Executive Secretary of U.S.-Japan Cooperative Cancer Research Program
National Cancer Institute
NIH, Building 31, Room 11A19
Bethesda, Maryland 20014, U.S.A.

Observer

Dr. Justin L. Bloom
Counselor for Scientific and
Technological Affairs, Embassy of the
United States of America

JAPAN

Dr. Haruo Sugano
Director, Cancer Institute
Japanese Foundation for Cancer Research
Toshima-ku, Tokyo 170, Japan

Dr. Osahiko Abe
Professor, Department of Surgery
School of Medicine, Keio University
Shinjuku-ku, Tokyo 169, Japan

Dr. Kenji Inoue
Professor, Department of Surgery
School of Medicine, Tokushima University
Kuramoto-cho, Tokushima 770, Japan

Dr. Masaru Izuo
Professor, Department of Surgery
School of Medicine, Gunma University
Maebashi, Gunma 371, Japan

Dr. Tamaki Kajitani
Director, Cancer Institute Hospital
Japanese Foundation for Cancer Research
Toshima-ku, Tokyo 170, Japan

Dr. Hiroki Koyama
Chief, Department of Surgery
The Center for Adult Diseases
Higashinari-ku, Osaka 530, Japan

Dr. Kanji Kubo
Chief, Breast Service Unit
National Nagoya Hospital
Naka-ku, Nagoya 460, Japan

Dr. Keijiro Kuno
Chief, Department of Surgery
Cancer Institute Hospital
Japanese Foundation for Cancer Research
Toshima-ku, Tokyo 170, Japan

Dr. Keishi Matsumoto
Professor, Institute for Cancer Research
Osaka University Medical School
Kita-ku, Osaka 530, Japan

Dr. Hiroshi Nagasawa
Chief, Pharmacology Division
National Cancer Center Research Institute
Chuo-ku, Tokyo 104, Japan

Dr. Yasuo Nomura
Chief, Department of Breast Surgery
National Kyushu Cancer Center Hospital
Minami-ku, Fukuoka 815, Japan

Dr. Makoto Ogawa
Chief, Division of Clinical Chemotherapy
Cancer Chemotherapy Center
Japanese Foundation for Cancer Research
Toshima-ku, Tokyo 170, Japan

Dr. Goi Sakamoto
Associate, Department of Pathology
Cancer Institute
Japanese Foundation for Cancer Research
Toshima-ku, Tokyo 170, Japan

Dr. Yoshio Sakurai
Director, Cancer Chemotherapy Center
Japanese Foundation for Cancer Research
Toshima-ku, Tokyo 170, Japan

Dr. Takashi Tsuruo
Associate, Division of Experimental Chemotherapy
Cancer Chemotherapy Center
Japanese Foundation for Cancer Research
Toshima-ku, Tokkyo 170, Japan

Dr. Minoru Yoshida
Chief, Section of Breast Surgery
Aichi Cancer Center Hospital
Chikusa-ku, Nagoya 464, Japan

Observers

Dr. Hugo Concetti
Department of Pathology Cancer Institute
Japanese Foundation for Cancer Research
Toshima-ku, Tokyo 170, Japan

Dr. Koji Enomoto
Lecturer, Department of Surgery
School of Medicine, Keio University
Shinjuku-ku, Tokyo 169, Japan

Dr. Atsuo Fukami
Department of Surgery
Cancer Institute Hospital
Japanese Foundation for Cancer Research
Toshima-ku, Tokyo 170, Japan

Dr. Noboru Horikoshi
Division of Clinical Chemotherapy
Cancer Chemotherapv Center
Japanese Foundation for Cancer Research
Toshima-ku, Tokyo 170, Japan

Dr. Yoji Ikawa
Member and Chief
Department of Viral Oncology
Cancer Institute
Japanese Foundation for Cancer Research
Toshima-ku, Tokyo 170, Japan

Dr. Jiro Inagaki
Division of Clinical Chemotherapy
Cancer Chemotherapy Center
Japanese Foundation for Cancer Research
Toshima-ku, Tokyo 170, Japan

Dr. Akio Matsuzawa
Instructor, Laboratory Animal Research Center
The Institute of Medical Science
University of Tokyo
Minato-ku, Tokyo 108, Japan

Dr. Tadaoki Morimoto
Assistant, Department of Surgery
School of Medicine, Tokushima University
Kuramoto-cho, Tokushima 770, Japan

Dr. Ken Tominaga
Chief, Department of Surgery
Tokyo Metropolitan Kamogame Hospital
Bunkyo-ku, Tokyo 113, Japan

Dr. Shigeru Tsukagoshi
Chief, Division of Experimental Chemotherapy
Cancer Chemotherapy Center
Japanese Foundation for Cancer Research
Toshima-ku, Tokyo 170, Japan

Dr. Hiroshi Yamamoto
Head, Department of Surgery
National Cancer Center Hospital
Chuo-ku, Tokyo 104, Japan